课题基金 / 基金详情

CYCLOPHOSPHAMIDE,DOXORUBICIN & ETOPOSIDE +DDI & GCSF IN HIV+ NONHODGKINS LYMPHOMA

CYCLOPHOSPHAMIDE,DOXORUBICIN & ETOPOSIDE +DDI & GCSF IN HIV+ NONHODGKINS LYMPHOMA
环磷酰胺、阿霉素
批准号：
6305862
负责人：
BRUCE RAPHAEL
金额：
$2.1万
依托单位：
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
依托单位国家：
美国
项目类别：
财政年份：
1999
资助国家：
美国
项目状态：
已结题
起止时间：
1999-12-01 至 2000-11-30
来源：
https://reporter.nih.gov/project-details/6305862
关键词：
2'3' dideoxyinosine AIDS related neoplasm /cancer AIDS therapy HIV infections clinical research colony stimulating factor combination cancer therapy cyclophosphamide doxorubicin drug screening /evaluation etoposide human subject human therapy evaluation nonHodgkin's lymphoma

项目摘要

项目成果

BRUCE RAPHAEL的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This Phase II, multicenter trial has several primary objectives. The first is to evaluate the complete response rate, progression-free survival, and survival of patients with HIV-related intermediate and high-grade Non-Hodgkin's Lymphoma (NHL) treated with infusional cyclophosphamide, doxorubicin, and etopside (CDE) plus didanosine (ddI). Toxicity and event-free survival, such as death, progression of lymphoma, or AIDS-defining event, will also be evaluated. Patients will be statified according to CD4 counts and CNS involvement.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CYCLOPHOSPHAMIDE,DOXORUBICIN & ETOPOSIDE +DDI & GCSF IN HIV+ NONHODGKINS LYMPHOMA